The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zoton FasTab 30 mg oro-dispersible tablets

30 milligram(s) Orodispersible tablet

Pfizer Healthcare IrelandPA0822/101/003

Main Information

Trade NameZoton FasTab 30 mg oro-dispersible tablets
Active SubstancesLansoprazole
Strength30 milligram(s)
Dosage FormOrodispersible tablet
Licence HolderPfizer Healthcare Ireland
Licence NumberPA0822/101/003

Group Information

ATC CodeA02BC Proton pump inhibitors
A02BC03 lansoprazole


Licence Issued16/11/2001
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0008-033-033
Interchangeable List DocumentPDF of Interchangeable List
« Back